JP2020510845A5 - - Google Patents

Info

Publication number

JP2020510845A5

JP2020510845A5 JP2019566047A JP2019566047A JP2020510845A5 JP 2020510845 A5 JP2020510845 A5 JP 2020510845A5 JP 2019566047 A JP2019566047 A JP 2019566047A JP 2019566047 A JP2019566047 A JP 2019566047A JP 2020510845 A5 JP2020510845 A5 JP 2020510845A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

seq

antagonist antibody

sema4d

subject

Prior art date

2018-02-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108010056102 CD100 antigen Proteins 0.000 claims description 80
• 102100027744 Semaphorin-4D Human genes 0.000 claims description 80
• 239000005557 antagonist Substances 0.000 claims description 65
• 230000004190 glucose uptake Effects 0.000 claims description 48
• 239000012634 fragment Substances 0.000 claims description 47
• 208000023105 Huntington disease Diseases 0.000 claims description 27
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 26
• 208000027418 Wounds and injury Diseases 0.000 claims description 26
• 230000006378 damage Effects 0.000 claims description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
• 208000035475 disorder Diseases 0.000 claims description 26
• 208000014674 injury Diseases 0.000 claims description 26
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 26
• 230000000626 neurodegenerative effect Effects 0.000 claims description 26
• 210000004556 brain Anatomy 0.000 claims description 24
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
• 239000000427 antigen Substances 0.000 claims description 15
• 108091007433 antigens Proteins 0.000 claims description 15
• 102000036639 antigens Human genes 0.000 claims description 15
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
• 208000037048 Prodromal Symptoms Diseases 0.000 claims description 8
• 208000010877 cognitive disease Diseases 0.000 claims description 6
• 230000002068 genetic effect Effects 0.000 claims description 6
• 238000012360 testing method Methods 0.000 claims description 6
• ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
• 102100034384 Plexin-B1 Human genes 0.000 claims description 4
• 101710100559 Plexin-B1 Proteins 0.000 claims description 4
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 101150043003 Htt gene Proteins 0.000 claims description 3
• 238000010176 18-FDG-positron emission tomography Methods 0.000 claims description 2
• 208000024827 Alzheimer disease Diseases 0.000 claims description 2
• 206010003591 Ataxia Diseases 0.000 claims description 2
• 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 2
• 206010048962 Brain oedema Diseases 0.000 claims description 2
• 208000028698 Cognitive impairment Diseases 0.000 claims description 2
• 201000010374 Down Syndrome Diseases 0.000 claims description 2
• 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 2
• 208000018737 Parkinson disease Diseases 0.000 claims description 2
• 102100034383 Plexin-B2 Human genes 0.000 claims description 2
• 101710100551 Plexin-B2 Proteins 0.000 claims description 2
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
• 206010044688 Trisomy 21 Diseases 0.000 claims description 2
• 208000006752 brain edema Diseases 0.000 claims description 2
• 208000011235 central nervous system lupus Diseases 0.000 claims description 2
• 206010015037 epilepsy Diseases 0.000 claims description 2
• 238000003384 imaging method Methods 0.000 claims description 2
• 230000003993 interaction Effects 0.000 claims description 2
• 201000010901 lateral sclerosis Diseases 0.000 claims description 2
• 230000031864 metaphase Effects 0.000 claims description 2
• 208000005264 motor neuron disease Diseases 0.000 claims description 2
• 210000003205 muscle Anatomy 0.000 claims description 2
• 238000002600 positron emission tomography Methods 0.000 claims description 2
• 208000020431 spinal cord injury Diseases 0.000 claims description 2
• 238000006467 substitution reaction Methods 0.000 claims description 2
• 230000009529 traumatic brain injury Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 28
• 239000000203 mixture Substances 0.000 claims 1
• 230000019491 signal transduction Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 32
• 238000011156 evaluation Methods 0.000 description 3
• 208000024806 Brain atrophy Diseases 0.000 description 2
• 206010061296 Motor dysfunction Diseases 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1